All lobbying filings

TULIPIFERA STRATEGIES

TULIPIFERA STRATEGIES filed a Q4 report for TREATMENT ADVOCACY CENTER on January 14, 2026, reporting $10,000 in lobbying income.

Lobbying for TREATMENT ADVOCACY CENTER · Advocacy, education, and research related to eliminating barriers to the treatment of SMI.

All filings by TULIPIFERA STRATEGIES · Everything TREATMENT ADVOCACY CENTER has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 14, 2026

Income

$10,000

What the client paid this registrant for the period.

Client based in

Virginia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Medicaid IMD Exclusion. The IMD Exclusion, within Sec. 1905(a) of the Social Security Act, generally excludes federal fund participation for treatment provided in an inpatient psychiatric facility. Medicare lifetime limit on impatient psychiatric care. Medicare generally imposes a 190 day lifetime limit on treatment provided in an inpatient psychiatric facility.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.